Lem Fui Fui, Opook Fernandes, Lee Dexter Jiunn Herng, Chee Fong Tyng, Lawson Fahcina P, Chin Su Na
Clinical Research Centre, Hospital Queen Elizabeth, Ministry of Health Malaysia, Kota Kinabalu, Malaysia.
Wildlife Health, Genetic and Forensic Laboratory, Kota Kinabalu, Malaysia.
Front Pharmacol. 2021 Feb 12;11:585331. doi: 10.3389/fphar.2020.585331. eCollection 2020.
The emergence of COVID-19 as a pandemic has resulted in the need for urgent development of vaccines and drugs and the conduction of clinical trials to fight the outbreak. Because of the time constraints associated with the development of vaccines and effective drugs, drug repurposing and other alternative treatment methods have been used to treat patients that have been infected by the SARS-CoV-2 virus and have acquired COVID-19. The objective of this systematic scoping review is to provide an overview of the molecular mechanism of action of repurposed drugs or alternative treatment medicines used to attenuate COVID-19 disease. The research articles or gray literature, including theses, government reports, and official news online, were identified from four databases and one search engine. The full content of a total of 160 articles that fulfilled our inclusion criteria was analyzed and information about six drugs (ritonavir, lopinavir, oseltamivir, remdesivir, favipiravir, and chloroquine) and four Traditional Chinese Medicines (, TCM combination of and , and ) was extracted. All of the repurposed drugs and complementary medicine that have been used for the treatment of COVID-19 depend on the ability of the drug to inhibit the proliferation of the SARS-CoV-2 virus by binding to enzyme active sites, viral chain termination, or triggering of the molecular pathway, whereas Traditional Chinese Medicine plays a pivotal role in triggering the inflammation pathway, such as the neuraminidase blocker, to fight the SARS-CoV-2 virus.
新型冠状病毒肺炎大流行的出现导致迫切需要开发疫苗和药物,并进行临床试验以抗击疫情。由于疫苗和有效药物研发存在时间限制,药物重新利用及其他替代治疗方法已被用于治疗感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)并患上新型冠状病毒肺炎的患者。本系统综述的目的是概述用于减轻新型冠状病毒肺炎病情的重新利用药物或替代治疗药物的分子作用机制。从四个数据库和一个搜索引擎中识别出研究文章或灰色文献,包括论文、政府报告和在线官方新闻。对总共160篇符合纳入标准的文章的全文进行了分析,并提取了有关六种药物(利托那韦、洛匹那韦、奥司他韦、瑞德西韦、法匹拉韦和氯喹)和四种中药(、的中药组合和)的信息。所有用于治疗新型冠状病毒肺炎的重新利用药物和补充药物都依赖于药物通过与酶活性位点结合、病毒链终止或触发分子途径来抑制SARS-CoV-2病毒增殖的能力,而中药在触发炎症途径(如神经氨酸酶阻滞剂)以对抗SARS-CoV-2病毒方面发挥着关键作用。